Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week Low – Here’s Why

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $41.05 and last traded at $41.16, with a volume of 61717 shares trading hands. The stock had previously closed at $41.49.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $62.83.

Supernus Pharmaceuticals Trading Down 1.4%

The company has a 50-day simple moving average of $46.07 and a 200 day simple moving average of $48.01. The company has a market cap of $2.38 billion, a P/E ratio of -21.30, a P/E/G ratio of 0.77 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The company had revenue of $219.06 million during the quarter, compared to analysts’ expectations of $205.31 million. During the same period in the prior year, the business earned $0.40 EPS. The company’s quarterly revenue was up 32.4% on a year-over-year basis. On average, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its stake in Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after purchasing an additional 193,479 shares in the last quarter. Mystic Asset Management Inc. purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth $1,181,000. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $434,871,000. Allworth Financial LP bought a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $2,357,000. Finally, Rice Hall James & Associates LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $22,800,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company’s portfolio addresses conditions including epilepsy, migraine and attention-deficit/hyperactivity disorder (ADHD), with an emphasis on extended-release and other drug-delivery technologies.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain epilepsy indications and the prevention of migraine headaches.